2026 Q3 - tulosraportti
UUTTA
4 päivää sitten
‧1 t 3 min
3,75 DKK/osake
Viimeisin osinko
4,34%Tuotto/v
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 23 | ||
| 4 391 | ||
| 23 | ||
| 1 029 | ||
| 1 180 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 3.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 4.11. | ||
2026 Q2 - tulosraportti 5.8. | ||
2026 Q1 - tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 - tulosraportti 4.2. |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·51 min sittenA post hoc analysis of adults with MASH and liver scar tissue who had a BMI under 27 kg/m² showed that markers of liver injury, fibrosis, and disease activity improved at week 72 in participants receiving semaglutide 2.4 mg as a weekly injection, compared to placebo. Non-invasive biomarkers of fibrosis, including ELF and PRO-C3, also showed a result in favor of semaglutide 2.4 mg over placebo, providing information on fibrosis as a supplement to biopsy-based endpoints. Together with the histological results from the ESSENCE study, these findings contribute to the evidence base for semaglutide 2.4 mg in individuals with MASH, liver scar tissue, and a BMI under 27 kg/m² – a patient group that may be overlooked, as MASH is often associated with severe obesity. Plainsboro, New Jersey, USA and Bagsværd, Denmark, November 8, 2026 – Novo Nordisk today announced results from a post hoc analysis of the phase 3 ESSENCE study. The analysis included a subgroup of 106 adults with metabolic dysfunction-associated steatohepatitis (MASH) and liver scar tissue who had a BMI under 27 kg/m². At week 72, an improvement was seen in a range of liver-related parameters in participants receiving semaglutide 2.4 mg as a weekly injection, compared to placebo. This included liver enzymes and non-invasive markers of disease activity and fibrosis, among others. The results were presented at an oral presentation at The Liver Meeting® 2026 in Denver, Colorado.1 "MASH can affect individuals regardless of body type. Symptoms are often not immediately noticeable, and if the disease remains undiagnosed and untreated, it can lead to severe health complications," states Michelle Skinner Moore, PhD, MBA, Vice President for Medical Affairs at Novo Nordisk. "This analysis focuses on adults with a BMI under 27 – a group that has received less attention in the discussion on MASH, as the disease is often associated with severe obesity. By examining markers of liver injury, disease activity, and fibrosis in individuals who received semaglutide 2.4 mg, we have gained greater insight into this group. This can help qualify the treatment of individuals living with MASH."Out of the 800 randomized participants included in the 72-week interim analysis of the first part of the ESSENCE study, 106 had a BMI below 27 kg/m². The estimated treatment effects at week 72 are shown below. Liver-related parameters at week 72 in adults with MASH and liver scar tissue as well as a BMI < 27 kg/m² Endpoint Semaglutide 2.4 mg vs. placebo at week 72 Markers of liver injury ALT ETR 0.61 (95% CI: 0.48; 0.79) AST ETR 0.67 (95% CI: 0.56; 0.80) Disease activity FAST score ETD -0.13 (95% CI: -0.26; -0.01) Fibrosis markers ELF score ETD -0.45 (95% CI: -0.73; -0.17) PRO-C3 ETR 0.82 (95% CI: 0.71; 0.95) VCTE-LSM ETR 0.88 (95% CI: 0.73; 1.06)† *Values are estimated effects of semaglutide 2.4 mg compared with placebo, given with 95% confidence intervals. ETR = estimated treatment ratio; ETD = estimated treatment difference. ETR values below 1 and ETD values below 0 indicate a benefit with semaglutide 2.4 mg. †95% confidence interval (CI) for VCTE-LSM included 1.0. ALT = alanine aminotransferase; AST = aspartate aminotransferase; FAST = FibroScan-AST; ELF = Enhanced Liver Fibrosis; PRO-C3 = marker of type III collagen formation; VCTE-LSM = liver stiffness measurement using vibration-controlled transient elastography.1 Exploratory post-hoc analyses are hypothesis-generating, and further investigations into the clinical validity of these results would be valuable. The results complement the histological data reported for this subgroup regarding both primary endpoints: resolution of steatohepatitis without worsening of liver fibrosis, and improvement of liver fibrosis without worsening of steatohepatitis.1 "This analysis is not about a single biomarker, but suggests a pattern across measures of liver injury, disease activity and fibrosis," says Professor Jörn Schattenberg, Head of the Department of Medicine II (Gastroenterology and Hepatology) at Saarland University Medical Center in Homburg and Saarland University in Germany. "Together with the histological findings, these data underline a crucial point: Body size alone does not define MASH, nor should it determine who is taken seriously regarding MASH."- ·1 t sittenIt has been an eventful week for Novo Nordisk. I have summarized the week's most important news in this post: https://x.com/investseekers/status/2119488930051416103?a=IAKf6ohcPZv5PgXIiOs&s=20
·2 t sitten · MuokattuNovo Nordisk strengthens its position in China – obesity sales rise 162 % Novo Nordisk takes yet another important step in the battle for the Chinese market for obesity and diabetes treatment. The company is expanding its collaboration with some of China's largest pharmacy chains and simultaneously strengthening its partnership with the digital health platform JD Health. The collaboration with the pharmacy chains Gaoji Health, Dashenlin and Yifeng Pharmacy collectively comprises a network of approximately 53,000 stores. This provides Novo Nordisk with a significantly stronger distribution platform and the opportunity to reach out to far more patients with counseling, treatment and follow-up. At the same time, the collaboration with JD Health is being expanded with AI-based health services, digital patient support and better integration between online and offline treatment. The purpose is to create a more cohesive treatment pathway for patients with overweight, obesity and diabetes. The expansion comes at a time when Novo is experiencing particularly strong growth in China. In the third quarter of 2026, sales of obesity treatments rose by a full 162 % compared to the same period last year to 326 mio. kr. Wegovy was the primary driver behind the growth, even though the company continues to experience price pressure on the Chinese market. Novo Nordisk also used the trade fair in Shanghai to present Kyinsu (IcoSema), a new weekly combination treatment that brings together basal insulin and semaglutide in a single injection. China became the first country in the world where the treatment was launched commercially in July 2026. At the same time, Novo's insulin sales in China rose by 17 % in the third quarter to 2.93 mia. kr., which underscores the strength of the company's existing diabetes business. Strategically, the development is interesting because Novo Nordisk is not only increasing sales of Wegovy, but also investing heavily in the infrastructure that is to support future growth. The expanded distribution network and the collaboration with JD Health can become an important advantage when the company eventually seeks to introduce new treatments such as oral Wegovy and CagriSema on the Chinese market, provided that the products obtain the necessary approvals.
·7 t sittenSome people in here really ought to consider if Novo shares have taken over their lives - It is weekend!! Thought damn well that it didn't keep going on the weekends as some imply, it damn well did, sick.
What else should we do? Quality time with family? There is no time for that with money in Novo
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q3 - tulosraportti
UUTTA
4 päivää sitten
‧1 t 3 min
3,75 DKK/osake
Viimeisin osinko
4,34%Tuotto/v
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·51 min sittenA post hoc analysis of adults with MASH and liver scar tissue who had a BMI under 27 kg/m² showed that markers of liver injury, fibrosis, and disease activity improved at week 72 in participants receiving semaglutide 2.4 mg as a weekly injection, compared to placebo. Non-invasive biomarkers of fibrosis, including ELF and PRO-C3, also showed a result in favor of semaglutide 2.4 mg over placebo, providing information on fibrosis as a supplement to biopsy-based endpoints. Together with the histological results from the ESSENCE study, these findings contribute to the evidence base for semaglutide 2.4 mg in individuals with MASH, liver scar tissue, and a BMI under 27 kg/m² – a patient group that may be overlooked, as MASH is often associated with severe obesity. Plainsboro, New Jersey, USA and Bagsværd, Denmark, November 8, 2026 – Novo Nordisk today announced results from a post hoc analysis of the phase 3 ESSENCE study. The analysis included a subgroup of 106 adults with metabolic dysfunction-associated steatohepatitis (MASH) and liver scar tissue who had a BMI under 27 kg/m². At week 72, an improvement was seen in a range of liver-related parameters in participants receiving semaglutide 2.4 mg as a weekly injection, compared to placebo. This included liver enzymes and non-invasive markers of disease activity and fibrosis, among others. The results were presented at an oral presentation at The Liver Meeting® 2026 in Denver, Colorado.1 "MASH can affect individuals regardless of body type. Symptoms are often not immediately noticeable, and if the disease remains undiagnosed and untreated, it can lead to severe health complications," states Michelle Skinner Moore, PhD, MBA, Vice President for Medical Affairs at Novo Nordisk. "This analysis focuses on adults with a BMI under 27 – a group that has received less attention in the discussion on MASH, as the disease is often associated with severe obesity. By examining markers of liver injury, disease activity, and fibrosis in individuals who received semaglutide 2.4 mg, we have gained greater insight into this group. This can help qualify the treatment of individuals living with MASH."Out of the 800 randomized participants included in the 72-week interim analysis of the first part of the ESSENCE study, 106 had a BMI below 27 kg/m². The estimated treatment effects at week 72 are shown below. Liver-related parameters at week 72 in adults with MASH and liver scar tissue as well as a BMI < 27 kg/m² Endpoint Semaglutide 2.4 mg vs. placebo at week 72 Markers of liver injury ALT ETR 0.61 (95% CI: 0.48; 0.79) AST ETR 0.67 (95% CI: 0.56; 0.80) Disease activity FAST score ETD -0.13 (95% CI: -0.26; -0.01) Fibrosis markers ELF score ETD -0.45 (95% CI: -0.73; -0.17) PRO-C3 ETR 0.82 (95% CI: 0.71; 0.95) VCTE-LSM ETR 0.88 (95% CI: 0.73; 1.06)† *Values are estimated effects of semaglutide 2.4 mg compared with placebo, given with 95% confidence intervals. ETR = estimated treatment ratio; ETD = estimated treatment difference. ETR values below 1 and ETD values below 0 indicate a benefit with semaglutide 2.4 mg. †95% confidence interval (CI) for VCTE-LSM included 1.0. ALT = alanine aminotransferase; AST = aspartate aminotransferase; FAST = FibroScan-AST; ELF = Enhanced Liver Fibrosis; PRO-C3 = marker of type III collagen formation; VCTE-LSM = liver stiffness measurement using vibration-controlled transient elastography.1 Exploratory post-hoc analyses are hypothesis-generating, and further investigations into the clinical validity of these results would be valuable. The results complement the histological data reported for this subgroup regarding both primary endpoints: resolution of steatohepatitis without worsening of liver fibrosis, and improvement of liver fibrosis without worsening of steatohepatitis.1 "This analysis is not about a single biomarker, but suggests a pattern across measures of liver injury, disease activity and fibrosis," says Professor Jörn Schattenberg, Head of the Department of Medicine II (Gastroenterology and Hepatology) at Saarland University Medical Center in Homburg and Saarland University in Germany. "Together with the histological findings, these data underline a crucial point: Body size alone does not define MASH, nor should it determine who is taken seriously regarding MASH."
- ·1 t sittenIt has been an eventful week for Novo Nordisk. I have summarized the week's most important news in this post: https://x.com/investseekers/status/2119488930051416103?a=IAKf6ohcPZv5PgXIiOs&s=20
- ·2 t sitten · MuokattuNovo Nordisk strengthens its position in China – obesity sales rise 162 % Novo Nordisk takes yet another important step in the battle for the Chinese market for obesity and diabetes treatment. The company is expanding its collaboration with some of China's largest pharmacy chains and simultaneously strengthening its partnership with the digital health platform JD Health. The collaboration with the pharmacy chains Gaoji Health, Dashenlin and Yifeng Pharmacy collectively comprises a network of approximately 53,000 stores. This provides Novo Nordisk with a significantly stronger distribution platform and the opportunity to reach out to far more patients with counseling, treatment and follow-up. At the same time, the collaboration with JD Health is being expanded with AI-based health services, digital patient support and better integration between online and offline treatment. The purpose is to create a more cohesive treatment pathway for patients with overweight, obesity and diabetes. The expansion comes at a time when Novo is experiencing particularly strong growth in China. In the third quarter of 2026, sales of obesity treatments rose by a full 162 % compared to the same period last year to 326 mio. kr. Wegovy was the primary driver behind the growth, even though the company continues to experience price pressure on the Chinese market. Novo Nordisk also used the trade fair in Shanghai to present Kyinsu (IcoSema), a new weekly combination treatment that brings together basal insulin and semaglutide in a single injection. China became the first country in the world where the treatment was launched commercially in July 2026. At the same time, Novo's insulin sales in China rose by 17 % in the third quarter to 2.93 mia. kr., which underscores the strength of the company's existing diabetes business. Strategically, the development is interesting because Novo Nordisk is not only increasing sales of Wegovy, but also investing heavily in the infrastructure that is to support future growth. The expanded distribution network and the collaboration with JD Health can become an important advantage when the company eventually seeks to introduce new treatments such as oral Wegovy and CagriSema on the Chinese market, provided that the products obtain the necessary approvals.
- ·7 t sittenSome people in here really ought to consider if Novo shares have taken over their lives - It is weekend!! Thought damn well that it didn't keep going on the weekends as some imply, it damn well did, sick.What else should we do? Quality time with family? There is no time for that with money in Novo
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 23 | ||
| 4 391 | ||
| 23 | ||
| 1 029 | ||
| 1 180 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 3.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 4.11. | ||
2026 Q2 - tulosraportti 5.8. | ||
2026 Q1 - tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 - tulosraportti 4.2. |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q3 - tulosraportti
UUTTA
4 päivää sitten
‧1 t 3 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 3.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 4.11. | ||
2026 Q2 - tulosraportti 5.8. | ||
2026 Q1 - tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 - tulosraportti 4.2. |
Tuotteita joiden kohde-etuutena tämä arvopaperi
3,75 DKK/osake
Viimeisin osinko
4,34%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·51 min sittenA post hoc analysis of adults with MASH and liver scar tissue who had a BMI under 27 kg/m² showed that markers of liver injury, fibrosis, and disease activity improved at week 72 in participants receiving semaglutide 2.4 mg as a weekly injection, compared to placebo. Non-invasive biomarkers of fibrosis, including ELF and PRO-C3, also showed a result in favor of semaglutide 2.4 mg over placebo, providing information on fibrosis as a supplement to biopsy-based endpoints. Together with the histological results from the ESSENCE study, these findings contribute to the evidence base for semaglutide 2.4 mg in individuals with MASH, liver scar tissue, and a BMI under 27 kg/m² – a patient group that may be overlooked, as MASH is often associated with severe obesity. Plainsboro, New Jersey, USA and Bagsværd, Denmark, November 8, 2026 – Novo Nordisk today announced results from a post hoc analysis of the phase 3 ESSENCE study. The analysis included a subgroup of 106 adults with metabolic dysfunction-associated steatohepatitis (MASH) and liver scar tissue who had a BMI under 27 kg/m². At week 72, an improvement was seen in a range of liver-related parameters in participants receiving semaglutide 2.4 mg as a weekly injection, compared to placebo. This included liver enzymes and non-invasive markers of disease activity and fibrosis, among others. The results were presented at an oral presentation at The Liver Meeting® 2026 in Denver, Colorado.1 "MASH can affect individuals regardless of body type. Symptoms are often not immediately noticeable, and if the disease remains undiagnosed and untreated, it can lead to severe health complications," states Michelle Skinner Moore, PhD, MBA, Vice President for Medical Affairs at Novo Nordisk. "This analysis focuses on adults with a BMI under 27 – a group that has received less attention in the discussion on MASH, as the disease is often associated with severe obesity. By examining markers of liver injury, disease activity, and fibrosis in individuals who received semaglutide 2.4 mg, we have gained greater insight into this group. This can help qualify the treatment of individuals living with MASH."Out of the 800 randomized participants included in the 72-week interim analysis of the first part of the ESSENCE study, 106 had a BMI below 27 kg/m². The estimated treatment effects at week 72 are shown below. Liver-related parameters at week 72 in adults with MASH and liver scar tissue as well as a BMI < 27 kg/m² Endpoint Semaglutide 2.4 mg vs. placebo at week 72 Markers of liver injury ALT ETR 0.61 (95% CI: 0.48; 0.79) AST ETR 0.67 (95% CI: 0.56; 0.80) Disease activity FAST score ETD -0.13 (95% CI: -0.26; -0.01) Fibrosis markers ELF score ETD -0.45 (95% CI: -0.73; -0.17) PRO-C3 ETR 0.82 (95% CI: 0.71; 0.95) VCTE-LSM ETR 0.88 (95% CI: 0.73; 1.06)† *Values are estimated effects of semaglutide 2.4 mg compared with placebo, given with 95% confidence intervals. ETR = estimated treatment ratio; ETD = estimated treatment difference. ETR values below 1 and ETD values below 0 indicate a benefit with semaglutide 2.4 mg. †95% confidence interval (CI) for VCTE-LSM included 1.0. ALT = alanine aminotransferase; AST = aspartate aminotransferase; FAST = FibroScan-AST; ELF = Enhanced Liver Fibrosis; PRO-C3 = marker of type III collagen formation; VCTE-LSM = liver stiffness measurement using vibration-controlled transient elastography.1 Exploratory post-hoc analyses are hypothesis-generating, and further investigations into the clinical validity of these results would be valuable. The results complement the histological data reported for this subgroup regarding both primary endpoints: resolution of steatohepatitis without worsening of liver fibrosis, and improvement of liver fibrosis without worsening of steatohepatitis.1 "This analysis is not about a single biomarker, but suggests a pattern across measures of liver injury, disease activity and fibrosis," says Professor Jörn Schattenberg, Head of the Department of Medicine II (Gastroenterology and Hepatology) at Saarland University Medical Center in Homburg and Saarland University in Germany. "Together with the histological findings, these data underline a crucial point: Body size alone does not define MASH, nor should it determine who is taken seriously regarding MASH."
- ·1 t sittenIt has been an eventful week for Novo Nordisk. I have summarized the week's most important news in this post: https://x.com/investseekers/status/2119488930051416103?a=IAKf6ohcPZv5PgXIiOs&s=20
- ·2 t sitten · MuokattuNovo Nordisk strengthens its position in China – obesity sales rise 162 % Novo Nordisk takes yet another important step in the battle for the Chinese market for obesity and diabetes treatment. The company is expanding its collaboration with some of China's largest pharmacy chains and simultaneously strengthening its partnership with the digital health platform JD Health. The collaboration with the pharmacy chains Gaoji Health, Dashenlin and Yifeng Pharmacy collectively comprises a network of approximately 53,000 stores. This provides Novo Nordisk with a significantly stronger distribution platform and the opportunity to reach out to far more patients with counseling, treatment and follow-up. At the same time, the collaboration with JD Health is being expanded with AI-based health services, digital patient support and better integration between online and offline treatment. The purpose is to create a more cohesive treatment pathway for patients with overweight, obesity and diabetes. The expansion comes at a time when Novo is experiencing particularly strong growth in China. In the third quarter of 2026, sales of obesity treatments rose by a full 162 % compared to the same period last year to 326 mio. kr. Wegovy was the primary driver behind the growth, even though the company continues to experience price pressure on the Chinese market. Novo Nordisk also used the trade fair in Shanghai to present Kyinsu (IcoSema), a new weekly combination treatment that brings together basal insulin and semaglutide in a single injection. China became the first country in the world where the treatment was launched commercially in July 2026. At the same time, Novo's insulin sales in China rose by 17 % in the third quarter to 2.93 mia. kr., which underscores the strength of the company's existing diabetes business. Strategically, the development is interesting because Novo Nordisk is not only increasing sales of Wegovy, but also investing heavily in the infrastructure that is to support future growth. The expanded distribution network and the collaboration with JD Health can become an important advantage when the company eventually seeks to introduce new treatments such as oral Wegovy and CagriSema on the Chinese market, provided that the products obtain the necessary approvals.
- ·7 t sittenSome people in here really ought to consider if Novo shares have taken over their lives - It is weekend!! Thought damn well that it didn't keep going on the weekends as some imply, it damn well did, sick.What else should we do? Quality time with family? There is no time for that with money in Novo
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 23 | ||
| 4 391 | ||
| 23 | ||
| 1 029 | ||
| 1 180 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt